GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » 12-1 Month Momentum %

Blueprint Medicines (LTS:0HOJ) 12-1 Month Momentum % : 62.46% (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-23), Blueprint Medicines's 12-1 Month Momentum % is 62.46%.

The industry rank for Blueprint Medicines's 12-1 Month Momentum % or its related term are showing as below:

LTS:0HOJ's 12-1 Month Momentum % is ranked better than
88.93% of 1482 companies
in the Biotechnology industry
Industry Median: -26.745 vs LTS:0HOJ: 62.46

Competitive Comparison of Blueprint Medicines's 12-1 Month Momentum %

For the Biotechnology subindustry, Blueprint Medicines's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's 12-1 Month Momentum % falls into.



Blueprint Medicines  (LTS:0HOJ) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Blueprint Medicines  (LTS:0HOJ) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Blueprint Medicines 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (LTS:0HOJ) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (LTS:0HOJ) Headlines

No Headlines